FTEAA 是一类 4- 苯乙烯基哌啶抑制剂。FTEAA 对单胺氧化酶 (MAO) 有强抑制作用,IC50分别为 0.52 μM (MAO-A),1.02 μM (MAO-B)。MAO 抑制剂已用于心血管、神经和肿瘤的研究。
生物活性 | FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards bothmonoamine oxidasewithIC50s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research[1][2]. |
IC50& Target | MAO-A 0.52 μM (IC50) | MAO-B 1.02 μM (IC50) |
|
体外研究 (In Vitro) | MAO-A and MAO-B act function to lower central nervous system (CNS) concentration of monoamines, regulate the amount and activity of available monoamines[1]. If dopamine levels are too high, MAO levels will increase to compensate. If serotonin levels are too low, then MAO activity will decrease to leave adequate serotonin supplies for the CNS to function optimally[1]. FTEAA inhibits MAO-A and MAO-B with micromolar scale IC50s of 0.52 and 1.02 μM, respectively[2].
|
体内研究 (In Vivo) | FTEAA exhibits total clearance of 0.446 log/mL/min/kg, and the tolerable dose is prescribed to be 0.513 log mg/kg/day[2]. Predicted Pharmacokinetic Analysis of FTEAA[2]
Intestinal Absorption (%) | Total Clearance (log/mL/min/kg) | Max. Tolerable Dose(log mg/kg/day) | RO5 Rulea | 95.664 | 0.812 | 0.493 | yes | a: the molecular weight of the drug must not exceed 500 g/mol, hydrogen bond donors must be under five, hydrogen bond acceptors must essentially be less than ten, its lipophilicity (log P) should not cross the digit five, and the number of rotatable bonds must be less than 10.
|
分子量 | |
Formula | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |